Friday, 23 Aug 2019

You are here

RheumNow Week in Review – 30 September 2016

Dr. Jack Cush Reviews highlights in the news and journals from the past week on RheumNow.com:

  1. Proteomic analysis of RA gut microbiome shows unique citrulline peptides - gut mucosa may contribute to ACPA in RA. http://buff.ly/2cVh4Cz
  2. Indomethacin treatment of mice w/ premalignant lesions shows cancer slowing - PGE2 inhibition results in more CD8 Tcells and IFN http://buff.ly/2dvtLcF
  3. Prime Therapeutics shows Xeljanz discontinuations at 30% by 6mos & 44% at 1 yr. 10% use it before MTX/other DMARDs https://t.co/PwqAzkiIij
  4. Taiwan study of HIV population and risk of autoimmune disease showed higher risk for Sjögrens (SIR=1.64), psoriasis (2.05), SLE (2.59), AIHA (35.06), Uveitis (2.50) https://t.co/qsgODbKKxW
  5. Yale study of Alopecia (areata or universalis) showed 32% of 66 pts improved with tofacitinib 5mg bid after 3 months. https://t.co/DBmnWEujiM
  6. IL-6 inhibitor (PF-04236921) NOT effective in SLE;186 pts RCT- 3 doses same as placebo in SRI-4, BICLA responses https://t.co/xBc3D9ONH3
  7. Scleroderma Renal Crisis review: 3-5 yrs after onset; acute rise in BP & creat, oliguria, 1/2 with thrombotic angiopathy https://t.co/KqSgJ9DiUl
  8. EGPA (Churg-Strauss)157 pts:12y delay in Dx, severe asthma predates systemic symptoms by 12 yrs, asthma worse 3-6mo before Dx https://t.co/7Ab3nFnLjJ
  9. Rates of Septic arthritis increased 43% in UK (5.5-->7.8/100k) over last 15yrs, especially in elderly >75. https://t.co/WLJ2J8QGtK
  10. Serious infections in RA are related to disease activity. The risk with biologics is most likely in 1st 6mos of use. https://t.co/0tPxF1BrZo
  11. RA pts (vs non RA) more likely to get Rx: GI Rxs, Abx, thyroid, tricyclics, asthma/inhaled steroids, PPI, HTN Rxs. https://t.co/aLMHoaunCH
  12. 5 severe PSS patients getting transplants were Rx w/ immunosuppressives; showed improvement in skin & lung function… https://t.co/t1a9a0plgh
  13. NSAIDs Pose a Dose-Related Risk for Heart Failure Hospitalizations
  14. ICD-10 Grace Period Ends October 1st
  15. Anti-Sclerostin Drug Prevents Vertebral Fractures in Post-Menopausal Osteoporosis 
  16. FDA Approves New Amgen Biosimilar for Adalimumab - Amjevita (generically called adalimumab-atto) becomes the fourth biosimilar to be FDA approved 
  17. FDA Approves Stelara for Crohn's Colitis  
  18. Ilaris Gets FDA Approval for Rare Febrile Disorders 
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com: MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.